Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Synta halts study of lung cancer treatment, stock plummets

Synta Pharmaceuticals Corp has decided to end a late-stage trial of its lung cancer treatment after an independent review said it proved ineffective, nearly halving its stock in extended trading on Tuesday. Lexington, Massachusetts-based Synta’s shares were down 46.6 percent at $1.09 after the bell. The late stage study aimed to see if a combination […]

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

April 2019 Focus: Healthcare agency & network profiles, industry overview & awards, and more!

Subscribe

Ad Right Bottom